Royce & Associates LP Supernus Pharmaceuticals, Inc. Transaction History

Royce & Associates LP

$10.5 Billion
Q3 2024

24 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 09, 2023	BUY	$27.57 - $32.91 $516,937 - $617,062	18,750 New	18,750 $516,000
Q1 2023 May 04, 2023	SELL	$34.93 - $42.03 $6,427 - $7,733	-184 Reduced 0.42%	43,619 $1.58 Million
Q4 2022 May 23, 2023	BUY	$31.09 - $37.88 $5,720 - $6,969	184 Added 0.42%	43,803 $1.56 Million
Q4 2022 Feb 13, 2023	SELL	$31.09 - $37.88 $28,975 - $35,304	-932 Reduced 2.08%	43,803 $1.56 Million
Q3 2022 Nov 03, 2022	SELL	$28.79 - $35.41 $4,491 - $5,523	-156 Reduced 0.35%	44,735 $1.51 Million
Q2 2022 Aug 04, 2022	SELL	$25.33 - $34.25 $225,918 - $305,475	-8,919 Reduced 16.57%	44,891 $1.3 Million
Q1 2022 May 05, 2022	SELL	$28.51 - $32.9 $5.82 Million - $6.72 Million	-204,314 Reduced 79.15%	53,810 $1.74 Million
Q4 2021 Feb 07, 2022	SELL	$26.37 - $34.22 $2.99 Million - $3.87 Million	-113,201 Reduced 30.49%	258,124 $7.53 Million
Q3 2021 Nov 10, 2021	BUY	$23.54 - $31.39 $104,282 - $139,057	4,430 Added 1.21%	371,325 $9.9 Million
Q2 2021 Aug 06, 2021	SELL	$26.72 - $33.19 $253,946 - $315,437	-9,504 Reduced 2.52%	366,895 $11.3 Million
Q1 2021 May 10, 2021	SELL	$24.15 - $31.45 $261,592 - $340,666	-10,832 Reduced 2.8%	376,399 $9.85 Million
Q4 2020 Feb 08, 2021	BUY	$17.7 - $25.81 $1.58 Million - $2.3 Million	89,053 Added 29.87%	387,231 $9.74 Million
Q3 2020 Nov 12, 2020	BUY	$20.2 - $25.05 $1.03 Million - $1.28 Million	51,149 Added 20.71%	298,178 $6.21 Million
Q2 2020 Aug 07, 2020	BUY	$17.09 - $24.89 $239,721 - $349,132	14,027 Added 6.02%	247,029 $5.87 Million
Q1 2020 May 12, 2020	SELL	$14.45 - $24.69 $238,425 - $407,385	-16,500 Reduced 6.61%	233,002 $4.19 Million
Q4 2019 Feb 06, 2020	BUY	$19.93 - $29.13 $639,613 - $934,869	32,093 Added 14.76%	249,502 $5.92 Million
Q3 2019 Nov 13, 2019	BUY	$25.47 - $33.37 $5.18 Million - $6.78 Million	203,189 Added 1428.9%	217,409 $5.97 Million
Q2 2019 Aug 12, 2019	BUY	$29.96 - $38.87 $189,287 - $245,580	6,318 Added 79.95%	14,220 $471,000
Q1 2019 May 09, 2019	BUY	$32.77 - $41.99 $258,948 - $331,804	7,902 New	7,902 $277,000
Q3 2018 Nov 13, 2018	SELL	$42.7 - $56.55 $2.48 Million - $3.28 Million	-58,000 Closed	0 $0
Q2 2018 Aug 09, 2018	SELL	$44.1 - $59.85 $396,900 - $538,650	-9,000 Reduced 13.43%	58,000 $3.47 Million
Q1 2018 May 14, 2018	SELL	$37.15 - $46.9 $1.19 Million - $1.5 Million	-32,000 Reduced 32.32%	67,000 $3.07 Million
Q4 2017 Feb 09, 2018	SELL	$36.4 - $42.6 $2.18 Million - $2.56 Million	-60,000 Reduced 37.74%	99,000 $3.95 Million
Q2 2017 Aug 07, 2017	BUY	N/A	159,000	159,000 $6.85 Million

Others Institutions Holding SUPN

# of Institutions

283

Shares Held

60.6M

Call Options Held

27.7K

Put Options Held

11.3K

Black Rock Inc. New York, NY

10.4M
Shares

$410 Million
0.01% of portfolio
Vanguard Group Inc Valley Forge, PA

6.13M
Shares

$242 Million
0.0% of portfolio
Armistice Capital, LLC New York, NY

5.1M
Shares

$201 Million
2.64% of portfolio
Dimensional Fund Advisors LP Austin, TX

2.88M
Shares

$114 Million
0.02% of portfolio
Macquarie Group LTD Australia, C3

2.63M
Shares

$104 Million
0.09% of portfolio

View Full List

About SUPERNUS PHARMACEUTICALS, INC.

Ticker SUPN
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 53,495,300
Market Cap $2.11B
Description
Supernus Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. Its commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prop...

More about SUPN

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Royce & Associates LP, based on Form 13F filings with the SEC.

News

Stay updated on Royce & Associates LP with notifications on news.

Account